KEYTRUDA
100mgKEYTRUDA100mg
KEYTRUDA (pembrolizumab) 100mg is a revolutionary PD-1 checkpoint inhibitor immunotherapy used to treat multiple cancer types including melanoma, lung cancer, and head and neck cancer.
Key Benefits
- World's leading immuno-oncology medication
- FDA-approved for more cancer indications than any other immunotherapy
- Blocks PD-1 to unleash immune response against cancer
- Durable responses that can last after treatment completion
- Both monotherapy and combination options available
- Convenient 3-week or 6-week dosing schedules
Contact Us for Pricing
Get a written quote against a prescription within 24 hours for KEYTRUDA 100mg. Our team is available 24/7.
Direct line: +44 7429 917553
Prescription required
We do not proceed without one
Licensed Türkiye channels
İTS serial-traceable by karekod
Delivered in person
Not shipped by courier
Written reply
Quote within 24 hours
How KEYTRUDA Works
KEYTRUDA works by blocking a protein called PD-1 (Programmed Death-1) on the surface of T-cells, which are key immune cells that fight cancer. Cancer cells often express a protein called PD-L1 that binds to PD-1, essentially putting a "brake" on the immune system and allowing cancer cells to evade detection.
By blocking the PD-1/PD-L1 interaction, KEYTRUDA releases this brake and allows T-cells to recognize and attack cancer cells more effectively. This mechanism is known as checkpoint inhibition and represents a fundamental shift from traditional chemotherapy, which directly attacks cancer cells but also damages healthy cells.
KEYTRUDA enhances the body's natural anti-tumor immune response, potentially leading to durable responses that can last even after treatment ends. Unlike chemotherapy, immunotherapy with KEYTRUDA can create immunologic memory, where the immune system continues to recognize and fight cancer cells.
About KEYTRUDA 100mg
KEYTRUDA (pembrolizumab) 100mg/4mL by Merck (MSD) is the world's leading immuno-oncology medication that has fundamentally changed cancer treatment. As a humanized monoclonal antibody that blocks the PD-1 pathway, KEYTRUDA unleashes the body's own immune system to recognize and attack cancer cells. KEYTRUDA is FDA-approved for more cancer indications than any other immunotherapy, including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high (MSI-H) cancers, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, renal cell carcinoma, and many more. Working through licensed Turkish pharmacy channels, we provide authentic KEYTRUDA from MSD with complete documentation, proper cold chain handling, and a written quote against a prescription, usually within 24 hours. Our experienced team ensures reliable international delivery for hospitals, oncology centers, and pharmaceutical distributors worldwide. Contact us via WhatsApp for current availability and pricing.
Common Uses
- Melanoma (advanced and adjuvant)
- Non-small cell lung cancer (NSCLC)
- Head and neck squamous cell carcinoma
- Classical Hodgkin lymphoma
- Urothelial carcinoma (bladder cancer)
- MSI-H/dMMR solid tumors
- Gastric/GEJ adenocarcinoma
- Esophageal cancer
- Cervical cancer
- Hepatocellular carcinoma
- Renal cell carcinoma
- Triple-negative breast cancer
- Endometrial carcinoma
Dosage Information
KEYTRUDA dosing has been simplified with weight-based and flat dosing options:
Standard Adult Dosing (most indications):
Pediatric Dosing (for approved indications):
Administration:
Duration of Treatment:
Dose modifications are not typically made for KEYTRUDA; instead, treatment may be delayed or discontinued for immune-related adverse events.
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store KEYTRUDA vials in the original carton to protect from light. Refrigerate at 2°C to 8°C (36°F to 46°F). Do not freeze. Do not shake.
Prior to infusion, allow the vial to reach room temperature (approximately 30 minutes). The diluted solution may be stored at room temperature for up to 6 hours from the time of dilution, including room temperature storage and infusion time. If refrigerated, allow the diluted solution to come to room temperature before administration.
The diluted solution may be stored under refrigeration at 2°C to 8°C for up to 24 hours from the time of dilution. Do not freeze the diluted solution.
Discard any unused portion left in the vial. KEYTRUDA does not contain a preservative.
We ensure proper cold chain handling during shipping to maintain product integrity.
Full prescribing monograph
A single reference page compiled from the manufacturer's prescribing information and the regulator's public product data. No pricing is published on it.
Frequently Asked Questions About KEYTRUDA
Find answers to common questions about ordering, pricing, and shipping.
Related Oncology Medications Products
Explore more oncology medications medications from our catalog
